Case Journey | How ADCs are Transforming HER2-Low Metastatic Breast Cancer Treatment

Tune into our debut episode of OncoTalks Case Journey as Dr. Paul Conkling and Dr. Mabel Mardones discuss two compelling cases of metastatic ER-positive breast cancer, emphasizing the role of antibody drug conjugates (ADCs) in treatment. They explore the challenges of HER2-low classification and the importance of early access to innovative therapies for improving patient outcomes. The conversation highlights the need for precise diagnostic approaches and the evolving landscape of breast cancer.  Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.